OncoHub.ai
An abstract digest clustered by cancer type and ranked by clinical priority. Numerical results (HR, PFS, OS) are preserved; reliability caveats are embedded within each study's card.
Indication: High clinical-risk ER+/HER2−, mostly node-positive early breast cancer
Key finding: 4,429 patients. At Prosigna ROR ≤60, test-directed endocrine-only therapy was non-inferior to chemo+endocrine: 5-yr IBCFS 91.5% (control) vs 90.4%, HR 0.99 (90% CI 0.81–1.20), NI p=0.013; in the low-ROR population 94.9% vs 93.7%, HR 1.06 (90% CI 0.78–1.46), NI p=0.0051.
Clinical relevance: Patients with ROR ≤60 tumors (including premenopausal with OFS) can safely avoid chemotherapy.
Source: ASCO Abstract 500
Indication: High-risk early-stage TNBC
Key finding: Median follow-up 93.8 mo; 7-yr EFS 78.3% vs 69.8% (HR 0.68, 0.54–0.86); 7-yr OS 85.1% vs 77.2% (HR 0.64, 0.49–0.85); G≥3 treatment-related AE 77.1% vs 73.3%; any-grade immune-mediated AE 35.0% vs 13.1%.
Clinical relevance: Pembrolizumab sustains long-term EFS and OS benefit.
Source: ASCO Abstract 507
Indication: ER+/HER2−, stage I–III early breast cancer
Key finding: Pre-menopausal IDFS HR 0.65 (3-yr 94.0% vs 91.5%), DRFI HR 0.58; post-menopausal IDFS HR 0.74 (91.3% vs 88.3%), DRFI HR 0.76; metastatic-disease risk reduction pre-M 42%, post-M 24%.
Clinical relevance: IDFS/DRFI benefit regardless of menopausal status; fewer treatment discontinuations vs AI.
Source: ASCO Abstract 502
Indication: HR+/HER2−, node+ residual disease after NAC
Key finding: 135-mo median follow-up; 10-yr OS 89.9% vs 82.9%, adjusted HR 0.56 (95% CI 0.32–0.99; p=0.048); residual node+ subgroup OS HR 0.47.
Clinical relevance: Long-term OS benefit of non-cross-resistant chemotherapy demonstrated.
Source: ASCO Abstract 506
Indication: HR+/HER2− stage II/III EBC, adjuvant ribociclib
Key finding: ITT HR 0.71; biomarker population HR 0.72. PAM50 prognostic HRs: LumA reference, LumB 1.39, HER2E 2.62, BSL 3.92. RIB benefit across all subtypes; subtype × treatment interaction p=0.34.
Clinical relevance: Ribociclib benefit is consistent across all PAM50 subtypes.
Source: ASCO Abstract 501
Indication: Node-positive breast cancer, after NACT
Key finding: ypN0 rate: HR− HER2+ 86.1%, HR+ HER2+ 70.7%, TNBC 68.5%, HR+ HER2− 30.5% (p<0.001); ≥4 suspicious nodes vs 1–3 nodes 53.6% vs 54.4% (p=0.670).
Clinical relevance: Axillary response depends on tumor biology, not the initial nodal count.
Source: ASCO Abstract 505
Indication: Implant reconstruction after mastectomy
Key finding: 24-mo physical well-being pre-pectoral 79.2 vs sub-pectoral 74.3 (difference 4.8; 95% CI 1.0–8.7; p=0.01); implant loss/exchange within 24 mo 21.1% vs 14.5%.
Clinical relevance: Pre-pectoral improves long-term quality of life but carries a higher implant-loss risk.
Source: ASCO Abstract 504
Indication: Breast cancer with sentinel-node macrometastasis
Key finding: Randomized results for omitting complete axillary dissection; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the official presentation/publication full text.
Source: ASCO Abstract LBA503
Indication: HER2+ early/locally advanced breast cancer
Key finding: Neoadjuvant anbenitamab vs THP comparison; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA660
Indication: 1L metastatic castration-resistant prostate cancer (mCRPC)
Key finding: Median rPFS 24.8 vs 19.9 mo (HR 0.71; 95% CI 0.55–0.91; 1-sided p=0.0034); DRD-positive subgroup 27.7 vs 13.9 mo (HR 0.51; p=0.0039); G≥3 anemia 20.1%.
Clinical relevance: rPFS benefit across the whole population; more pronounced in DRD-positive patients.
Source: ASCO Abstract 5008
Indication: Metastatic hormone-sensitive prostate cancer (mHSPC)
Key finding: At Decipher GC >0.85, ADT+ENZ aHR 2.31 (95% CI 1.26–4.21; p=0.007); with ADT+ENZ+DOC aHR 1.08 (0.63–1.86); p-interaction = 0.043.
Clinical relevance: DGC >0.85 may identify patients who benefit from adding docetaxel to ADT+ENZ.
Source: ASCO Abstract 5001
Indication: mHSPC/mCRPC/nmCRPC
Key finding: At week 24, median change in the maximally affected cognitive domain −15.8% vs −36.1% (p=0.009); all crossovers were ENZ→DAR.
Clinical relevance: Darolutamide has a better cognitive profile than enzalutamide.
Source: ASCO Abstract 5005
Indication: mHSPC, exceptional responders to TS+ARPI
Key finding: At 18 months, 41% (32/78) remained treatment-free with eugonadal testosterone (80% CI 33.5–48.9; 1-sided p=0.0249); 67% recovered testosterone.
Clinical relevance: Planned treatment interruption is feasible in selected patients.
Source: ASCO Abstract 5004
Indication: High-volume metastatic hormone-naïve prostate cancer (mHNPC)
Key finding: 12-mo PSA<0.2 response rate 73% (95% CI 55.9–86.2; p<0.001); median rPFS 45.3 vs 31.1 mo (HR 0.62; 95% CI 0.28–1.37); 2 patients developed AML after prolonged talazoparib exposure.
Clinical relevance: Promising antitumor activity; the AML signal must be monitored.
Source: ASCO Abstract 5006
Indication: mHSPC (CHAARTED), prediction of docetaxel benefit
Key finding: In ST-DoxPCa-positive patients ADT+DOC HR 0.53 (95% CI 0.31–0.90; p=0.018); in negatives HR 1.32 (0.74–2.34; p=0.34).
Clinical relevance: Potential for personalized treatment intensification with an H&E-based biomarker.
Source: ASCO Abstract 5002
Indication: High-risk localized prostate cancer
Key finding: GC continuous MFS HR 1.19 (95% CI 1.10–1.29, p<0.001); OS HR 1.18; combined score ≥3 subgroup had a STAMPEDE M0-control-like prognosis.
Clinical relevance: Could expand the AAP-candidate pool by ~20%; 25% of very-high-risk patients could avoid AAP.
Source: ASCO Abstract 5000
Indication: HRR gene-altered metastatic castration-sensitive prostate cancer (mCSPC)
Key finding: Talazoparib + enzalutamide combination; full results released 30 May 08:00 ET, the abstract text was not available in this digest's source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA5007
Indication: Brain metastases 2–5 cm
Key finding: 6-mo surgical-bed local recurrence cumulative incidence 4.3% (95% CI 0–10.1); no LMD at 6 or 12 mo; 12-mo LR 16.4%; no symptomatic radionecrosis; 12-mo OS 76.5%.
Clinical relevance: A promising alternative to post-op FSRT.
Source: ASCO Abstract 2003
Indication: Intracranial lesions (mostly brain metastases)
Key finding: At month 3, 74% of patients had stable/improved cognitive performance; global composite Z difference +0.38 (p=0.001); 1-yr local control 98.5%.
Clinical relevance: Cognitive preservation can be achieved without compromising oncologic control.
Source: ASCO Abstract 2002
Indication: Melanoma with asymptomatic brain metastases
Key finding: Arm C (I+N) median OS 29.2 mo; 10-yr OS 31.2% (95% CI 13.0–49.4); in patients with low cfDNA tumor fraction median OS 22.3 vs 8.2 mo (p=0.033).
Clinical relevance: Long-term efficacy of I+N; cfDNA biomarker potential.
Source: ASCO Abstract 2008
Indication: Newly diagnosed GBM, ≥90% resection
Key finding: Median OS 21.7 vs 27.7 mo, HR 0.907 (91.5% CI 0.691–1.192; p=0.269); median PFS 9.5 vs 10.4 mo, HR 0.867.
Clinical relevance: Adding a carmustine wafer provides no OS benefit.
Source: ASCO Abstract 2001
Indication: Newly diagnosed GBM
Key finding: Q1 (early TMZ): median OS 16 vs 20 mo, HR 1.18 (0.89–1.56), p=0.24. Q2 (extended TMZ): 20 vs 18 mo, HR 0.82 (0.63–1.06), p=0.13; post-multivariate HR 0.73 (0.56–0.95).
Clinical relevance: Early TMZ does not improve OS; uncertainty remains for adjuvant TMZ beyond 6 cycles.
Source: ASCO Abstract 2004
Indication: Unresectable/partially resected high-grade glioma
Key finding: 12-mo OS 69.1% (95% CI 59–81); median OS 18.4 mo; H0 rejected (Z=1.29); one toxic death (febrile aplasia).
Clinical relevance: Potential survival improvement in poor-prognosis unresectable GBM.
Source: ASCO Abstract 2005
Indication: Newly diagnosed GBM
Key finding: Median OS MGMT-methylated 36.9 vs 25.3 mo (matched control); MGMT-unmethylated 19.0 vs 16.7 mo; in ex vivo immune responders OS improvement HR 0.26 (95% CI 0.09–0.77, p=0.015).
Clinical relevance: A personalized neoantigen vaccine can induce immune response; associated with OS.
Source: ASCO Abstract 2006
Indication: Advanced GIST, post-imatinib 2L
Key finding: Median PFS 16.5 (95% CI 13.8–19.2) vs 9.2 mo (7.2–11.0), HR 0.50 (0.39–0.65; P<0.0001); ORR 46% vs 26% (risk difference 20%; P<0.0001).
Clinical relevance: The combination reduces the risk of progression/death by 50% in 2L GIST.
Source: ASCO Abstract 11500
Indication: Progressive desmoid tumor
Key finding: PFS HR 0.16 (95% CI 0.07–0.38; P<0.0001); confirmed ORR 55.7% vs 9.1% (P<0.0001); 24-wk tumor-volume change LS mean −109.6 vs +122.8 cm³; worst-pain (WPI) change −2.24 vs +0.18 (P<0.0001); ovarian toxicity in premenopausal women 20/36 (56%).
Clinical relevance: The highest ORR reported for systemic Phase 3 desmoid therapy.
Source: ASCO Abstract / NCT04871282
Indication: Advanced conventional chondrosarcoma
Key finding: DCR 54.0% vs 27.5% (P=0.0005); ORR 5.8% vs 0 (P=0.0433); median time to pain worsening 2.76 vs 1.41 mo (HR 0.605; P=0.0033).
Clinical relevance: A potential first standard of care in this population.
Source: ASCO Abstract 11504
Indication: Advanced soft-tissue sarcoma (STS), 2L
Key finding: Median PFS trabectedin 2.9, eribulin 2.2, pazopanib 3.8 mo; pazopanib HR (vs trabectedin) 0.99 (0.63–1.56); DCR pazopanib 64.9%; mOS pazopanib 15.7 mo.
Clinical relevance: Pazopanib was selected for the Phase 3 comparison.
Source: ASCO Abstract 11508
Indication: Advanced GIST, 1L and 2L
Key finding: 2L median PFS 13.7 mo (95% CI 7.4–18.4); 1L ORR 61% (11/18); 2L ORR 35%; 2L dose reduction 6%.
Clinical relevance: Broad mutation coverage; rationale for Phase 3.
Source: ASCO Abstract 11501
Indication: Advanced clear cell sarcoma
Key finding: ORR 41.2% (7/17); DCR 70.6%; median PFS 4.14 mo; 6-mo PFS 42.8%; in the immunotherapy combination 4 patients discontinued for G4 rash.
Clinical relevance: Meaningful antitumor activity; risk of severe rash.
Source: ASCO Abstract 11503
Indication: Advanced synovial sarcoma, MAGE-A4+/HLA-A*02
Key finding: ORR 43.8% (95% CI 35.8–52.0); median DoR 7.1 mo; median OS 18.7 mo; in RECIST responders median OS 37.5 mo; CRS 73.2%.
Clinical relevance: Meaningful survival in this rare population.
Source: ASCO Abstract 11505
Indication: Advanced/metastatic alveolar soft part sarcoma (ASPS)
Key finding: ORR 26.8% (95% CI 15.8–40.3; below the pre-specified 31% threshold); mDOR 22.57 mo; mPFS 18.33 mo; mOS 59.27 mo; G≥3 TRAE 48.2%; one G5 event.
Clinical relevance: The ORR threshold was not met, but disease control and survival are prolonged.
Source: ASCO Abstract 11502
Indication: Resectable retroperitoneal liposarcoma (DDLPS, LMS)
Key finding: Complete resection 96%; Choi PR 26.7%; 3-yr PFS 70% (95% CI 56–83); 3-yr OS 85% (75–95); G3/4 neutropenia 21.4%.
Clinical relevance: Rationale for Phase 3.
Source: ASCO Abstract 11507
Indication: R/R LBCL, ASCT-ineligible
Key finding: Median PFS 11.6 vs 3.8 mo (HR 0.41; 95% CI 0.28–0.60); 2L: 17.6 vs 3.6 mo (HR 0.38); 3L+: HR 0.48; 2-yr PFS (2L) 40.3% vs 20.1%; G≥2 CRS 4%; no ICANS reported.
Clinical relevance: Marked efficacy in 2L; low toxicity.
Source: ASCO Abstract 7007
Indication: R/R mantle cell lymphoma (MCL)
Key finding: Median follow-up 41.5 mo; ORR 82%, CR 77%; median DoCR 40.8 mo; in the post-BTKi subgroup ORR 73.5%, CR 70.6%; G3-4 CRS 11.6%.
Clinical relevance: Durable efficacy in post-BTKi MCL.
Source: ASCO Abstract 7006
Indication: Newly diagnosed peripheral T-cell lymphoma (PTCL)
Key finding: CR after 6 cycles 55.9% (19/34); ORR 67.6%; G≥3 TEAE 55.9%.
Clinical relevance: Promising; a Phase 3 randomized trial has started (NCT06548347).
Source: ASCO Abstract 7004
Indication: R/R classic Hodgkin lymphoma (MTAP-deficient)
Key finding: At ≥DL7 (n=10) ORR 80%, CR 50%; G≥3 TEAE 28%; no DLTs.
Clinical relevance: Promising in heavily pretreated cHL.
Source: ASCO Abstract 7003
Indication: Elderly unfit/frail or anthracycline-ineligible newly diagnosed DLBCL
Key finding: CR after 6 cycles 86% (95% CI 65–97); 1-yr PFS 94.7% (68–99); CRS 55% (all G1).
Clinical relevance: Promising in the elderly/frail DLBCL population.
Source: ASCO Abstract 7002
Indication: EBV+ extranodal NK/T-cell lymphoma, post-remission
Key finding: 2-yr DFS 95.0% vs 77.6% (p=0.0347); deaths 0 vs 4 (16%); G≥3 AE 9.52% vs 16.00%.
Clinical relevance: A potential role for post-remission EBV-CTL therapy.
Source: ASCO Abstract 7005
Indication: HIV-associated DLBCL
Key finding: ORR 100%; CR 57%; 3-yr EFS/OS 83%/81%; non-GCB 3-yr EFS/OS 76%/63%.
Clinical relevance: Adding ibrutinib to R-da-EPOCH is tolerable.
Source: ASCO Abstract (Phase 1/2)
Indication: B-cell malignancies, CAR-T resistance
Key finding: L174V (rs2904880) MAF 76.3%; V/V homozygosity 65.2%.
Clinical relevance: Potential for pre-CAR-T CD19 genotyping in the Mediterranean population.
Source: ASCO Abstract 7008
Indication: Newly diagnosed DLBCL
Key finding: Phase 3 results; full text 30 May 08:00 ET, not available in this digest's source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA7000
Indication: 1L KRAS G12C+ NSCLC
Key finding: In the PD-L1+ cohort confirmed ORR 73% (95% CI 60–84), median PFS 19.3 mo (12.4–NE); in the PD-L1− cohort unconfirmed ORR 70%; G3/4 ALT increase 20%, AST 18%.
Clinical relevance: Phase 3 Krascendo 2 has been initiated.
Source: ASCO Abstract 8510
Indication: 1L KRAS G12C+ advanced NSCLC
Key finding: Monotherapy ORR 78.0% (32/41); pembrolizumab combination ORR 81.2% (39/48); in the PD-L1 TPS ≥50% subgroup ORR 95.0%; 6-mo PFS 68.9% (mono) / 74.6% (combo); G≥3 TRAE mono 7.0%, combo 32.7%.
Clinical relevance: First promising evidence for G12Ci monotherapy in 1L.
Source: ASCO Abstract 8511
Indication: EGFR L858R-mutant 1L NSCLC
Key finding: Phase 3 comparison; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA8518
Indication: Cisplatin-ineligible MIBC
Key finding: 18-wk post-op FACT-G change −2.73 vs −2.84 (no decrease vs control); BCI bowel/sexual scores worsened in both arms (sexual −15.46 vs −17.88).
Clinical relevance: Adding EV + pembrolizumab does not reduce HRQoL; given the efficacy benefit, it supports the risk/benefit profile.
Source: ASCO Abstract 4510
Indication: RCC after adjuvant pembrolizumab
Key finding: Mean DRS 14.9 (95% CI 8.5–21.3); 13% regret; long-standing/persistent toxicity associated with regret (26.9 LC vs 26.1 S vs 2.1 NS, p=0.0021); no difference CTCAE G1-2 vs G3-4 (p=0.23).
Clinical relevance: Long-term low-grade toxicity is the main driver of regret.
Source: ASCO Abstract 4512
Indication: Intermediate/high-risk resected RCC
Key finding: Adjuvant durvalumab monotherapy did not improve DFS versus active monitoring (full text 30 May 08:00 ET; numerical results were not available in the source, but the ASCO Daily News headline confirms the negative result).
Clinical relevance: Adjuvant durvalumab monotherapy appears to have no role in this setting.
Source: ASCO Abstract LBA4511
Indication: Resectable locally advanced melanoma
Key finding: Neoadjuvant daromun Phase 3 results; full text 30 May 08:00 ET, not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA9517
Indication: Anti-PD(L)-1-refractory Merkel cell carcinoma
Key finding: Tuvusertib ± avelumab Phase 2 results; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA9514
Indication: Resected stage I–IV colorectal cancer (CRC)
Key finding: In patients turning positive at the 2nd timepoint, adjuvant chemotherapy yielded DFS HR 0.3 (p=0.0165), 2-yr DFS 45.5% vs 9.8%; in those negative at both timepoints HR 0.8 (p=0.1744).
Clinical relevance: Early ctDNA dynamics may identify the subgroup that benefits from delayed ACT.
Source: ASCO Abstract 102
Indication: Cervical cancer screening (global health)
Key finding: 1,747/1,869 (93.5%) HR-HPV self-sampling completed; HR-HPV 5.1% (89/1747); 71.9% colposcopy; 4 patients with high-grade lesions/early invasive cancer 100% referred to treatment.
Clinical relevance: A scalable model exceeding WHO elimination targets.
Source: ASCO Abstract 1509
Indication: Various cancers, Mexican public center
Key finding: Of 228 immunotherapy-eligible patients, 114 (50%) were able to start; 42.1% could not start due to drug unavailability; 36.8% experienced treatment suspension; only 24.1% received guideline-concordant therapy.
Clinical relevance: An urgent need for supply-chain strategies.
Source: ASCO Abstract 1511
Indication: Oncology clinical research continuity
Key finding: 99% of planned patient visits and data transfers completed; 150 of 413 patients on active treatment/follow-up; 7,891 patient visits, 1,762 tumor response assessments.
Clinical relevance: Clinical research can continue in conflict zones with digital adaptation.
Source: ASCO Abstract 1512
This report was generated automatically and is not medical advice. Clinical decisions must be verified against official abstract/presentation full texts and current guidelines.
OncoHub.ai · ASCO 2026 Gündem
Bu içerik editoryaldir. Tıbbi tavsiye değildir. Klinik karar hekime aittir.
oncohub.ai →